Day: April 9, 2024

First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors from the enLIGHTEN™ Discovery Platform Delivery of two unique payload combinations, predicted in silico using the enLIGHTEN™ Advanced Analytics suite, was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor therapy in preclinical models of cancer This presentation accelerates the milestone associated with the second immunotherapy candidate based on the enLIGHTEN™ Discovery Platform, which was originally anticipated in the third quarter of 2024NEEDHAM, Mass., April 09, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...

Integrated BSS and OSS provide comprehensive and complete solutions for telecoms to leverage data and GenAI for faster time to market and new digital customer experiences TORONTO, April 09, 2024 (GLOBE NEWSWIRE) — Optiva Inc. (TSX: OPT), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today announced a strategic go-to-market partnership with GDi, a digital technology company with a complete portfolio for network planning, design and rollout. The partnership will provide communication service providers (CSPs) with pre-integrated and tested BSS and OSS software. As the telecom industry embraces GenAI opportunities, unifying and integrating billing and charging customer data with network management and operations support data has never been...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET. A live webcast of the virtual presentation will be available on the “Events and Presentations” page of the Investors section of the Company’s website with a replay available for 90 days following the event. For more information, please visit investors.effector.com. About eFFECTOR Therapeutics eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target...

BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting demonstrating that TPST-1120 reduces kidney cancer (RCC) growth as a monotherapy, while also showing increased inhibition when combined with frontline chemotherapy and immunotherapy. These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022. “Preclinical data presented at AACR further demonstrate that TPST-1120 has the potential to positively...

Acquisition Expands Golden Matrix’s Global Footprint and Significantly Increases Revenues LAS VEGAS, NV, April 09, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Golden Matrix Group Inc. (NASDAQ:GMGI)(“Golden Matrix” or the “Company”), a developer, licensor and global operator of online gaming and eCommerce platforms, systems and gaming content, today announced the closing of the previously announced acquisition agreement, pursuant to which Golden Matrix acquired ownership of the MeridianBet Group and its related companies, in a cash, debt and stock transaction. The acquisition was approved by Golden Matrix’s Board of Directors and by the Company’s shareholders at the special meeting held on March 19, 2024. The combination of the two companies’ dynamic business-to-business (B2B) and business-to-consumer (B2C) casino, sports betting...

The Company has finalized drillhole three planning and is pleased to announce the receipt of the Mineral Incentive Program – Junior Exploration Assistance grant of $115,500 VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) is pleased to announce the completion of drill planning for the third exploration drillhole at the Robinsons River Salt Project (the “Project”). The Company is currently   preparing for drill mobilization, scheduled to commence in April 2024. Furthermore, Vortex has been awarded a $115,500 grant from the Government of Newfoundland and Labrador, Department of Industry, Energy and Technology Mineral Incentive Program – Junior Exploration Assistance program. This grant is in recognition of prior exploration expenditures...

HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY) will host a conference call and webcast to discuss its third quarter fiscal year 2024 financial results at 10 a.m. EDT on Tuesday, April 30, 2024. All interested parties are invited to listen online at investors.sysco.com. Prior to the conference call and webcast, the company will also issue a news release and post a slide presentation in the investor relations section of its website. A replay of the webcast will be available online shortly after the live webcast is completed. For purposes of public disclosure, including this and future similar events, Sysco uses the investor relations section of its website, found at investors.sysco.com, as the primary channel for publishing key information to its investors, some of which may contain material and previously...

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior treatments in Bria-IMT™ population than in comparable studies Bria-IMT™ PFS compares favorably to their most recent treatment PFS in 48% of patients Clinical benefit rate of 56% in evaluable patients 71% intracranial objective response rate (iORR) in heavily pretreated patients Findings support clinical efficacy of Bria-IMT™ and highlight its significant potential in managing CNS metastatic disease in advanced breast cancer Additional preclinical anti-cancer data of Bria-OTS+™ and Bria-PROS+™ will be presented tomorrow 9:00 AM – 12:30 PM PST; Abstract Presentation Number: 6753PHILADELPHIA and...

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, welcomed Health Canada’s conduct of a Drug Establishment License (DEL) audit. The audit, which aims to expand the Company’s Good Manufacturing Practices (GMP) capabilities, follows the recent achievement of GMP certification for HYTN’s Kelowna production facility by Australia’s Therapeutic Goods Administration (TGA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standard. Securing a DEL will enhance HYTN’s current GMP manufacturing capabilities, facilitating the development and sale of additional compounds and product variations....